The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 06, 2018

Filed:

Sep. 09, 2015
Applicant:

Perosphere Inc., Danbury, CT (US);

Inventors:

Sasha Bakhru, Providence, RI (US);

Bryan Laulicht, Danbury, CT (US);

Stefan Zappe, Danbury, CT (US);

Solomon Steiner, Mount Kisco, NY (US);

Assignee:

Perosphere Technologies Inc., Danbury, CT (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/86 (2006.01); G01N 33/49 (2006.01); B01L 3/00 (2006.01); B01L 9/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/86 (2013.01); B01L 3/502715 (2013.01); B01L 9/527 (2013.01); G01N 33/4905 (2013.01); B01L 2300/0645 (2013.01); B01L 2300/0681 (2013.01); B01L 2300/0816 (2013.01); B01L 2300/1827 (2013.01);
Abstract

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.


Find Patent Forward Citations

Loading…